Literature DB >> 27593935

Aurora A kinase activates YAP signaling in triple-negative breast cancer.

S-S Chang1,2, H Yamaguchi1, W Xia1, S-O Lim1, Y Khotskaya3, Y Wu4, W-C Chang5, Q Liu6,7, M-C Hung1,2,5,8.   

Abstract

The Yes-associated protein (YAP) is an effector that transduces the output of the Hippo pathway to transcriptional modulation. Considering the role of YAP in cancers, this protein has emerged as a key node in malignancy development. In this study, we determined that Aurora A kinase acts as a positive regulator for YAP-mediated transcriptional machinery. Specifically, YAP associates with Aurora A predominantly in the nucleus. Activation of Aurora A can impinge on YAP activity through direct phosphorylation. Moreover, aberrant expression of YAP and Aurora A signaling is highly correlated with triple-negative breast cancer (TNBC). We herein provide evidence to establish the functional relevance of this newly discovered regulatory axis in TNBC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27593935     DOI: 10.1038/onc.2016.292

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.

Authors:  Hui Liu; Charles J Murphy; Florian A Karreth; Kristina B Emdal; Forest M White; Olivier Elemento; Alex Toker; Gerburg M Wulf; Lewis C Cantley
Journal:  Cancer Discov       Date:  2017-12-04       Impact factor: 39.397

2.  Bidirectional regulation of Aβ levels by Presenilin 1.

Authors:  Victor Bustos; Maria V Pulina; Yildiz Kelahmetoglu; Subhash C Sinha; Fred S Gorelick; Marc Flajolet; Paul Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

3.  The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors.

Authors:  Sarah Saab; Olin Shih-Shin Chang; Kentaro Nagaoka; Mien-Chie Hung; Hirohito Yamaguchi
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 4.  Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.

Authors:  Arijit Nath; Soham Mitra; Tanuma Mistry; Ranita Pal; Vilas D Nasare
Journal:  Med Oncol       Date:  2021-11-23       Impact factor: 3.064

Review 5.  The biology of YAP in programmed cell death.

Authors:  Yifan Cheng; Misha Mao; Yong Lu
Journal:  Biomark Res       Date:  2022-05-23

Review 6.  The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review.

Authors:  Anastasios Kyriazoglou; Michalis Liontos; Roubini Zakopoulou; Maria Kaparelou; Anna Tsiara; Alkistis Maria Papatheodoridi; Rebecca Georgakopoulou; Flora Zagouri
Journal:  Breast Care (Basel)       Date:  2020-05-12       Impact factor: 2.860

Review 7.  Protein Kinase Targets in Breast Cancer.

Authors:  Marilina García-Aranda; Maximino Redondo
Journal:  Int J Mol Sci       Date:  2017-11-27       Impact factor: 5.923

8.  RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.

Authors:  Siang-Boon Koh; Kenneth Ross; Steven J Isakoff; Nsan Melkonjan; Lei He; Karina J Matissek; Andrew Schultz; Erica L Mayer; Tiffany A Traina; Lisa A Carey; Hope S Rugo; Minetta C Liu; Vered Stearns; Adam Langenbucher; Srinivas Vinod Saladi; Sridhar Ramaswamy; Michael S Lawrence; Leif W Ellisen
Journal:  Clin Cancer Res       Date:  2021-06-24       Impact factor: 12.531

9.  Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment.

Authors:  Pareesa Kamgar-Dayhoff; Tinatin I Brelidze
Journal:  Oncotarget       Date:  2021-07-06

10.  Regulation of Yki/Yap subcellular localization and Hpo signaling by a nuclear kinase PRP4K.

Authors:  Yong Suk Cho; Jian Zhu; Shuangxi Li; Bing Wang; Yuhong Han; Jin Jiang
Journal:  Nat Commun       Date:  2018-04-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.